Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Histone-writer cancer drugs enter center stage

A Publisher Correction to this article was published on 14 August 2020

This article has been updated

Epizyme’s EZH2 inhibitor gains two approvals in quick succession — a milestone for this new class of epigenetic cancer drug that targets histone marks with greater precision than previous generations.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 14 August 2020

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Garber, K. Histone-writer cancer drugs enter center stage. Nat Biotechnol 38, 909–912 (2020). https://doi.org/10.1038/s41587-020-0621-1

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing